Publication In Focus: INSIGHT 2

The INSIGHT 2 study (NCT03940703) is an international, open-label, multicenter, Phase II trial investigating the combination of tepotinib plus osimertinib in MET-amplified non-small-cell lung cancer (NSCLC) and acquired resistance to first-line osimertinib. Future Oncology has recently published a clinical trial protocol of the study, discussing the rationale and design of the trial.

In this Publication In Focus feature, hear Professor Egbert Smit (Netherlands Cancer Institute, Amsterdam) discuss the recent publication in the Video Journal of Biomedicine’s video above, as well as visually understanding the article through the infographic linked below. Finally, the plain language summary can help patients, their family members and caregivers understand the article, also linked below.

Read the full paper

FEATURES

Plain language summary: A study to learn about the effects and safety of tepotinib plus osimertinib in patients with MET-amplified non-small cell lung cancer that has progressed after treatment with osimertinib (INSIGHT 2)

This plain language article may be helpful for patients with NSCLC and their family members or caregivers. It may also be helpful for patient advocates and healthcare professionals who are looking for treatment options for patients with advanced NSCLC.

 

Infographic: INSIGHT 2: a Phase II study of tepotinib plus osimertinib in MET-amplified NSCLC and first-line osimertinib resistance

This infographic visualizes the INSIGHT 2’s study key objectives, study design and outcomes.